CELL INTELLIGENCE · 肿瘤细胞治疗研究

从高比例急性髓系白血病原始细胞的白细胞单采物中学术制备抗 CD19 CAR-T 细胞

Academic manufacturing of anti-CD19 CAR-T cells from a leukapheresis with a high proportion of acute myeloid leukaemia blasts.

CAR-T 细胞治疗在儿童急性淋巴细胞白血病中的应用：面向普通儿科医师的综述

CART-Cell Therapy in Pediatric Acute Lymphoblastic Leukemia: A Review for General Pediatricians.

Tisagenlecleucel 用于年轻急性淋巴细胞白血病患者移植后复发：欧洲真实世界结局决定因素

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.

Tisa-cel 和 axi-cel 的 CAR 结构影响对 CD19-CAR-T 疗法耐药性的发展

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.

Obecabtagene Autoleucel 治疗复发/难治性 B-ALL：临床疗效与安全性的批判性综述

Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety.

尽管物流复杂性和高昂的获取成本仍是 CAR-T 细胞疗法的可及性障碍，obe-cel 的分子设计和安全性特征代表了 R/R B-ALL 患者治疗领域的重大进步。

探索长期疾病控制：Axicabtagene Ciloleucel CAR-T 细胞治疗或异基因造血细胞移植治疗复发/难治性大 B 细胞淋巴瘤

In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relap

与 allo-HCT 相比，axi-cel 为 r/r LBCL 患者提供了更优的 PFS 和 OS，主要归因于治疗相关死亡率更低，以及在细胞治疗前对化疗难治性疾病患者的疾病控制得到改善。

血液系统恶性肿瘤患者的抗真菌管理：从初级预防到经验性治疗与诊断驱动治疗

Antifungal Management in Patients with Hematological Malignancies: From Primary Prophylaxis to Empirical and Diagnosis-Driven Treatment.

将免疫治疗纳入儿童 B 细胞前体急性淋巴细胞白血病不断演变的标准治疗

Incorporating Immunotherapies into the Evolving Standard of Care for Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

B 细胞淋巴瘤与 B 细胞急性淋巴细胞白血病患者接受 CD19 靶向 CAR-T 细胞后发生噬血细胞性淋巴组织细胞增生症样综合征：来自 DESCAR-T 登记处的 LYSA、SFCE 与 GRAALL 研究

Hemophagocytic lymphohistiocytosis-like syndrome after CD19-directed CAR T-cells for B-cell lymphoma and B-cell acute lymphoblastic leukemia: A LYSA,

obecabtagene autoleucel 与外部对照臂在复发/难治性 B 细胞急性淋巴细胞白血病成人患者中的比较

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.